At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 108 enrolled
Drug / intervention
Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)drug
Likely dose
Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Cumulative Incidence of Major Cardiovascular Events of Ticagrelor in Taiwanese Patients With Non ST-segment Elevation Myocardial Infarction
In Brief
A Phase 4 clinical trial evaluating Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd) for Non ST-elevation Myocardial Infarction. Completed, enrolled 108 participants across 13 sites.
Detailed Summary
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the eletrocardiogram which presents the period when ventricles are depolarized) elevation myocardial infarction
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon ST-elevation Myocardial Infarction
CountriesTaiwan
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartApr 2015
Primary CompletionFeb 2017
TodayJul 2026
First PostedApr 2, 2015
Enrollment StartApr 23, 2015
Primary CompletionFeb 9, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.3 years ago
Interventions
Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)drug
Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)